Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTern Regulatory News (TERN)

Share Price Information for Tern (TERN)

Share Price is delayed by 15 minutes
Get Live Data
1.15    0.00 (0.00%)
Bid:
1.10
Ask:
1.20
Spread: 0.10 (9.091%)
Market Cap: £9.84m
TERN Live PriceLast checked at - London Stock Exchange

Intraday Tern Share Chart

Directorate Change

2 Dec 2010 09:50

RNS Number : 2496X
Chalkwell Investments PLC
02 December 2010
 



Chalkwell Investments plc.

("Chalkwell" or the "Company")

Appointment of Directors

 

Dated: 2 December 2010

Chalkwell, the AIM-quoted investment company, with a focus on the resource sector, is pleased to announce today the appointments of Mr. Bruce Evers as Executive Chairman and Mr. Reinhold Heus as Non-Executive Director with immediate effect.

Mr. Evers has a BA (Hons) degree in Modern Languages, Politics, History from Trinity College, University of Toronto. He started his career in 1983 as an Oil and Gas Analyst at Panmure Gordon, before moving to Laurence Prust, Schroder Securities, Yamaichi International (Europe) Limited and Investec, where he worked for 12 years. Subsequently, Mr. Evers worked as a Corporate Broker at Evolution Securities, Fairfax and BDR Securities.

Mr. Heus graduated with a BSc degree in Economics from Vrije Universiteit, Amsterdam. He started his career in 1982 with Royal Dutch Shell in Rotterdam as an Oil Trader before being promoted to Assistant to Head of Group Planning. Mr. Heus transferred to Royal Dutch Shell in London as a Business Development Manager in 1986 and was later an Acquisitions Manager. Mr. Heus was Director of International Mergers & Acquisitions for the Energy sector at Daiwa Securities from 1989 before becoming Head Emerging Markets Division. In 1995, Mr. Heus was the Head of Global Corporate Finance Division of ANZ Investment Bank before moving to 3i Group plc as a Senior Advisor to the Board. Since 2003, Mr. Heus has been a Director with Faircourt Capital Group Ltd, a private consulting firm focused on the global Energy & Resources sectors.

The following are details of all current and former directorships in the previous five years held by Mr. Bruce Evers and Mr. Reinhold Heus:

Full Name: Bruce George Alexander Evers

 Current Directorships

Former Directorships

30 Elsham Road London W14 Limited

BDR Securities Limited

-

Full Name: Reinhold Heus

 

 

Current Directorships

Former Directorships

Faircourt Capital Group Ltd

Faircourt Capital Limited

Faircourt Energy Limited

Faircourt Resources Limited

Faircourt Energy Group Limited

World Light Web Limited

 

Faircourt International Ltd

News Air Lease Limited

Transvision Resources Plc

Faircourt (Benelux) Ltd

Faircourt (Nordic) Ltd

Faircourt Group Limited

United African Airways Limited

Faircourt (Asia) Ltd

 

There are no further details to be disclosed under Rule 17 schedule 2 paragraph (f) of the AIM Rules in relation to Mr. Bruce Evers and Mr. Reinhold Heus.

 

ENDS

 

For further information please contact:

 

Chalkwell Investments plc

Nigel Weller, Director +44 (0)7769 906 906

 

Religare Capital Markets (Nomad)

Nick Harriss/Emily Staples +44 (0)20 7444 0800

 

Religare Capital Markets (Broker)

Daniel Briggs +44 (0)20 7444 0500

 

Bishopgate Communications

Michael Kinirons +44 (0)20 7562 3350

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGCBDDISGBGGD
Date   Source Headline
13th Apr 20212:00 pmRNSPrice Monitoring Extension
13th Apr 202111:05 amRNSSecond Price Monitoring Extn
13th Apr 202111:00 amRNSPrice Monitoring Extension
13th Apr 20219:05 amRNSSecond Price Monitoring Extn
13th Apr 20219:00 amRNSPrice Monitoring Extension
6th Apr 20214:40 pmRNSSecond Price Monitoring Extn
6th Apr 20214:35 pmRNSPrice Monitoring Extension
6th Apr 20212:06 pmRNSSecond Price Monitoring Extn
6th Apr 20212:00 pmRNSPrice Monitoring Extension
31st Mar 20217:01 amRNSDA convertible loan note maturity date extension
31st Mar 20217:00 amRNSFinal results for the year ended 31 December 2020
29th Mar 20213:40 pmRNSAIM Director Disclosure Update
29th Mar 20212:00 pmRNSPrice Monitoring Extension
25th Mar 202111:00 amRNSPrice Monitoring Extension
24th Mar 20212:06 pmRNSSecond Price Monitoring Extn
24th Mar 20212:00 pmRNSPrice Monitoring Extension
18th Mar 20214:41 pmRNSSecond Price Monitoring Extn
18th Mar 20214:35 pmRNSPrice Monitoring Extension
18th Mar 20212:06 pmRNSSecond Price Monitoring Extn
18th Mar 20212:00 pmRNSPrice Monitoring Extension
18th Mar 202111:05 amRNSSecond Price Monitoring Extn
18th Mar 202111:00 amRNSPrice Monitoring Extension
17th Mar 20212:06 pmRNSSecond Price Monitoring Extn
17th Mar 20212:01 pmRNSPrice Monitoring Extension
2nd Mar 20217:00 amRNSPortfolio News
11th Feb 20212:05 pmRNSSecond Price Monitoring Extn
11th Feb 20212:00 pmRNSPrice Monitoring Extension
8th Feb 20217:00 amRNSFundamentalVR and Device Authority Update
4th Feb 20217:00 amRNSPortfolio Update
28th Jan 20217:00 amRNSWyld Networks Fundraise and Update
15th Jan 202111:05 amRNSSecond Price Monitoring Extn
15th Jan 202111:00 amRNSPrice Monitoring Extension
13th Jan 20212:06 pmRNSSecond Price Monitoring Extn
13th Jan 20212:00 pmRNSPrice Monitoring Extension
13th Jan 202111:05 amRNSSecond Price Monitoring Extn
13th Jan 202111:00 amRNSPrice Monitoring Extension
12th Jan 20217:00 amRNSPortfolio Update
29th Dec 20204:41 pmRNSSecond Price Monitoring Extn
29th Dec 20204:35 pmRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSFurther FundamentalVR contract win
1st Dec 20205:30 pmRNSTotal Voting Rights
1st Dec 20207:00 amRNSFundamentalVR contract win
24th Nov 20207:00 amRNSFundamentalVR secures three-year follow on order
13th Nov 20204:41 pmRNSSecond Price Monitoring Extn
13th Nov 20204:36 pmRNSPrice Monitoring Extension
13th Nov 20207:00 amRNSResult of Fundraise
12th Nov 20204:36 pmRNSRetail Offer
12th Nov 20204:35 pmRNSEquity Fundraise of up to £2.2 million
10th Nov 20207:00 amRNSPortfolio Update
4th Nov 20207:00 amRNSInvestment in Talking Medicines Limited

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.